Get the Stockscreener App
9.61
3.22%
-0.32
Lexeo Therapeutics Inc stock is traded at $9.61, with a volume of 1.16M.
It is down -3.22% in the last 24 hours and up +15.50% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$9.93
Open:
$9.95
24h Volume:
1.16M
Relative Volume:
0.83
Market Cap:
$701.41M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-3.3929
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-6.24%
1M Performance:
+15.50%
6M Performance:
+119.41%
1Y Performance:
+44.08%
1-Day Range:
$8.9301
$9.95
1-Week Range:
$8.9301
$10.47
52-Week Range:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.61 | 724.76M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Biotechnology Select Industry Index - marketscreener.com
What dividend safety score for Lexeo Therapeutics Inc. stockGap Down & Low Drawdown Trading Strategies - Улправда
Why Lexeo Therapeutics Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Growth Portfolio Plans - Улправда
Why Lexeo Therapeutics Inc stock is a must watch in 2025Quarterly Risk Review & High Conviction Buy Zone Alerts - moha.gov.vn
Is Lexeo Therapeutics Inc. stock near bottom after declineTrade Risk Report & High Accuracy Investment Signals - Улправда
Lexeo Therapeutics Earnings Notes - Trefis
Will Lexeo Therapeutics Inc. stock deliver shareholder valuePortfolio Profit Report & High Accuracy Trade Alerts - Улправда
Dow Update: Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 PostEarnings & High Win Rate Trade Tips - Улправда
Bearish Setup: Is Lexeo Therapeutics Inc. stock near bottom after declineMarket Weekly Review & Risk Controlled Swing Alerts - ulpravda.ru
Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 News Drivers & Real-Time Stock Price Movement Reports - Улправда
Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target - marketscreener.com
This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation - Nasdaq
Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Certain Pre-Funded Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
54,001,214 Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Janus Henderson Group PLC Expands Stake in Lexeo Therapeutics Inc - GuruFocus
Aug Wrap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionStock Surge & Smart Allocation Stock Reports - moha.gov.vn
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Aug Action: What sentiment indicators say about Lexeo Therapeutics Inc stock - moha.gov.vn
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo Therapeutics' (LXEO) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics (LXEO) Rating Maintained as 'Buy' by Chardan Capital | LXEO Stock News - GuruFocus
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential - Investing.com Canada
Check Out Lexeo Therapeutics Inc (LXEO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Update Recap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Transcript : Lexeo Therapeutics, Inc.Special Call - marketscreener.com
Portfolio Update: Why Lexeo Therapeutics Inc stock remains resilientJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
How resilient is Lexeo Therapeutics Inc. stock in market downturnsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - marketscreener.com
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event - GlobeNewswire
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
A look into Lexeo Therapeutics Inc (LXEO)’s deeper side - setenews.com
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - Defense World
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):